Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P28676
UPID:
GRAN_HUMAN
Alternative names:
-
Alternative UPACC:
P28676; B2R5X3; Q53TB5; Q59EP3
Background:
Grancalcin is a calcium-binding protein known for its role in neutrophil adhesion to fibronectin and in the formation of focal adhesions. Its involvement in these critical cellular processes highlights its importance in cell motility and immune responses.
Therapeutic significance:
Understanding the role of Grancalcin could open doors to potential therapeutic strategies. Its pivotal role in immune cell function and adhesion mechanisms presents a unique opportunity for developing treatments targeting inflammatory diseases and immune response modulation.